Citius Oncology (NASDAQ:CTOR) Research Coverage Started at Maxim Group

Maxim Group initiated coverage on shares of Citius Oncology (NASDAQ:CTOR – Free Report) in a report issued on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $3.00 price objective on the stock. Citius Oncology Stock Down 2.2 % Citius Oncology stock opened at $0.92 on Wednesday. Citius Oncology has a 1-year […]

Leave a Reply

Your email address will not be published.

Previous post Insider Selling: Airbnb, Inc. (NASDAQ:ABNB) CEO Sells 76,923 Shares of Stock
Next post HC Wainwright Lowers MediWound (NASDAQ:MDWD) Price Target to $25.00